Pembrolizumab plus enfortumab vedotin in urothelial cancer

Nature Reviews Urology, Published online: 24 January 2024; doi:10.1038/s41585-024-00858-yThe combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.

Source: Nature Reviews Urology - January 24, 2024 Category: Urology & Nephrology Authors: Matteo Santoni Hideki Takeshita Francesco Massari Aristotelis Bamias Linda Cerbone Ondrej Fiala Veronica Mollica Sebastiano Buti Angela Santoni Joaquim Bellmunt Source Type: research